恩度联合顺铂对老年肿瘤患者恶性腹水的疗效

Effect of endostatin combined with cisplatin on elderly cancer patients with malignant ascites

目的采用腹腔给药的方式观察恩度联合顺铂对老年人难治性恶性腹水的临床疗效,生活质量的改善及免疫力的影响。方法收集经病理确诊的恶性腹腔积液老年患者64例。持续引流后,对照组:顺铂30 mg腹腔注射d1、d4、d7;21天重复,联合用药组(试验组):顺铂30 mg+恩度45 mg腹腔注射d1、d4、d7;21天为一疗程。两组均完成2个同期的治疗。通过实体瘤的疗效诊断标准(RECIST)评价两组临床疗效,通过美国国立癌症研究所(NCI)标准评价不良反应;通过心理问卷评估对患者焦虑、抑郁的改善,抽取静脉血,监测治疗前后CD4/CD8水平。结果试验组临床有效率高于对照组,显著改善了患者的焦虑及抑郁状态;试验组较对照组并未显著降低CD4/CD8。结论恩度联合顺铂提高腹水缓解率,未增加明显不良反应;改善焦虑抑郁状态;未降低患者的免疫力。

Objective To adopt intraperitoneal administration and observe the control group(Cisplatin)and combination group(endostatin combined with cisplatin)in order to see the effects on elderly patients with malignant ascites in clinical efficacy,the improvement of life quality and immunity.Methods Totally sixty-four elderly patients diagnosed with malignant ascites were collected.And they were divided into control group and combination group.Patients in control group were given 30 mg of cisplatin by intraperitoneal administration on day 1,day 4,day 7,respectively.And one cycle of treatment was 21 days.Patients in combination group were given 30 mg of cisplatin and 45 mg of endostatin(Endostar)by intraperitoneal administrationon day 1,day 4,day 7,respectively.And one course of treatment was 21 days.All patients in two groups were treated for two cycles.The efficacy evaluation criteria(RECIST)was used to evaluate clinical efficacy of two groups,and the side effects were evaluated by NCI.The improvement of anxiety and depression was evaluated by psychological questionnaire,and the level of CD4/CD8 was monitored before and after treatment.Results The efficacy of experimental group was higher than that of control group,which significantly improved the anxiety and depression of the patients;the CD4/CD8 of experimental group was not significantly lower than that of control group.Conclusion Endostar combined with cisplatin can improve the remission rate of ascites without obvious side effects,and they can also improve the state of anxiety and depression without reducing the immunity of patients.